Skip to main content
Erschienen in: International Journal of Colorectal Disease 1/2012

01.01.2012 | Original Article

Down-regulation of HLA-A mRNA in peripheral blood mononuclear cell of colorectal cancer

verfasst von: Ming-Chen Zhu, Yi-Jun Xu, Xiong Zou, Feng Yan

Erschienen in: International Journal of Colorectal Disease | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

It has been demonstrated that the alteration of human leukocyte antigen (HLA) class I expression frequently occurs in colorectal tumor. Previous studies mainly focused on the expression of HLA-A in tumor cells. The expression of HLA-A in peripheral blood mononuclear cells (PBMC) was unknown. To develop a non-invasive diagnostic method for colorectal cancer (CRC), this work investigated the expression of HLA-A mRNA in PBMC in patients with CRC.

Methods

Real-time quantitative RT-PCR was used to study the expression of HLA-A mRNA in PBMC from 48 patients with colorectal cancer, 38 patients with benign colorectal lesions, 20 patients with rheumatoid arthritis, 20 patients with esophageal cancer and 40 healthy individuals. Protein chip was utilized to detect the levels of serum CEA, CA 19-9, and CA 242 in all the cases. Overall results from the two methods were compared.

Results

The relative expression of HLA-A mRNA in PBMC was 1.11 ± 0.45 in healthy group, 0.81 ± 0.42 in benign colorectal lesion group, and 0.39 ± 0.34 in cancer group, respectively. The diagnostic sensitivity of HLA-A mRNA, CEA, CA19-9, and CA242 was 81%, 59%, 61%, and 63%, and their diagnostic specificity was 75%, 64%, 52%, and 67%, respectively.

Conclusions

The expression of HLA-A mRNA in PBMC from colorectal cancer group was significantly lower than those in both benign group and healthy group (P < 0.001). It could be potentially developed as a tumor assistant marker in future.
Literatur
1.
Zurück zum Zitat Pasetto LM, D'Andrea MR, Jirillo A et al (2006) Stable disease in advanced colorectal cancer: therapeutic implications. Anticancer Res 26:511–522PubMed Pasetto LM, D'Andrea MR, Jirillo A et al (2006) Stable disease in advanced colorectal cancer: therapeutic implications. Anticancer Res 26:511–522PubMed
2.
Zurück zum Zitat Popat S, Zhao D, Chen Z et al (2007) Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients. Anticancer Res 27:627–633PubMed Popat S, Zhao D, Chen Z et al (2007) Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients. Anticancer Res 27:627–633PubMed
3.
4.
Zurück zum Zitat Cummings LC, Payes JD, Cooper GS (2007) Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 109:718–726PubMedCrossRef Cummings LC, Payes JD, Cooper GS (2007) Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 109:718–726PubMedCrossRef
5.
Zurück zum Zitat Chen CD, Yen MF, Wang WM et al (2003) A case-cohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy. Br J Cancer 88:1866–1873PubMedCrossRef Chen CD, Yen MF, Wang WM et al (2003) A case-cohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy. Br J Cancer 88:1866–1873PubMedCrossRef
6.
Zurück zum Zitat Vermorken JB, Claessen AM, van Tinteren H et al (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345–350PubMedCrossRef Vermorken JB, Claessen AM, van Tinteren H et al (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345–350PubMedCrossRef
7.
Zurück zum Zitat Riethmuller G, Schneider Gadicke E, Schlimok G et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343:1177–1183PubMedCrossRef Riethmuller G, Schneider Gadicke E, Schlimok G et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343:1177–1183PubMedCrossRef
8.
Zurück zum Zitat Moertel CG, Fleming TR, Macdonald JS et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352–358PubMedCrossRef Moertel CG, Fleming TR, Macdonald JS et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352–358PubMedCrossRef
9.
Zurück zum Zitat Moller P, Koretz K, Schlag P et al (1991) Frequency of abnormal expression of HLA-A, B, C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrence. Int J Cancer Suppl 6:155–162PubMedCrossRef Moller P, Koretz K, Schlag P et al (1991) Frequency of abnormal expression of HLA-A, B, C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrence. Int J Cancer Suppl 6:155–162PubMedCrossRef
10.
Zurück zum Zitat Momburg F, Degener T, Bacchus E et al (1986) Loss of HLA-A, B, C and de novo expression of HLA-D in colorectal cancer. Int J Cancer 37:179–184PubMedCrossRef Momburg F, Degener T, Bacchus E et al (1986) Loss of HLA-A, B, C and de novo expression of HLA-D in colorectal cancer. Int J Cancer 37:179–184PubMedCrossRef
11.
Zurück zum Zitat McDougall CJ, Ngoi SS, Goldman IS et al (1990) Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res 50:8023–8027PubMed McDougall CJ, Ngoi SS, Goldman IS et al (1990) Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res 50:8023–8027PubMed
12.
Zurück zum Zitat Cordon CC, Fuks Z, Drobnjak M et al (1991) Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51:6372–6380 Cordon CC, Fuks Z, Drobnjak M et al (1991) Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51:6372–6380
13.
Zurück zum Zitat Ruiz CF, Lopez-Nevot MA, Gutierrez J et al (1989) Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. Clin Exp Metastasis 7:213–226CrossRef Ruiz CF, Lopez-Nevot MA, Gutierrez J et al (1989) Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. Clin Exp Metastasis 7:213–226CrossRef
14.
Zurück zum Zitat Lopez-Nevot MA, Esteban F, Ferron A et al (1989) HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 59:221–226PubMedCrossRef Lopez-Nevot MA, Esteban F, Ferron A et al (1989) HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 59:221–226PubMedCrossRef
15.
Zurück zum Zitat Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117–158PubMedCrossRef Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117–158PubMedCrossRef
16.
Zurück zum Zitat Seliger B, Cabrera T, Garrido F et al (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3–13PubMedCrossRef Seliger B, Cabrera T, Garrido F et al (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3–13PubMedCrossRef
17.
Zurück zum Zitat Menon AG, Janssen-van Rhijn CM, Morreau H et al (2004) Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 84:493–501PubMedCrossRef Menon AG, Janssen-van Rhijn CM, Morreau H et al (2004) Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 84:493–501PubMedCrossRef
18.
Zurück zum Zitat Miyagi T, Tatsumi T, Takehara T et al (2003) Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells. J Gastroenterol Hepatol 18:32–40PubMedCrossRef Miyagi T, Tatsumi T, Takehara T et al (2003) Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells. J Gastroenterol Hepatol 18:32–40PubMedCrossRef
19.
Zurück zum Zitat Le Morvan C, Cogne M, Drouet M (2001) HLA-A and HLA-B transcription decrease with ageing in peripheral blood leucocytes. Clin Exp Immunol 125:245–250PubMedCrossRef Le Morvan C, Cogne M, Drouet M (2001) HLA-A and HLA-B transcription decrease with ageing in peripheral blood leucocytes. Clin Exp Immunol 125:245–250PubMedCrossRef
20.
Zurück zum Zitat Le Morvan C, Cogne M, Drouet M (2001) An elevation in the concentration of HLA class I molecules in human blood due to ageing. Mech Ageing Dev 122:335–340PubMedCrossRef Le Morvan C, Cogne M, Drouet M (2001) An elevation in the concentration of HLA class I molecules in human blood due to ageing. Mech Ageing Dev 122:335–340PubMedCrossRef
21.
Zurück zum Zitat Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408PubMedCrossRef Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408PubMedCrossRef
22.
Zurück zum Zitat Bernards R, Dessain SK, Weinberg RA (1986) N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell 47:667–674PubMedCrossRef Bernards R, Dessain SK, Weinberg RA (1986) N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell 47:667–674PubMedCrossRef
23.
Zurück zum Zitat Versteeg R, van der Minne C, Plomp A et al (1990) N-myc expression switched off and class I human leukocyte antigen expression switched on after somatic cell fusion of neuroblastoma cells. Mol Cell Biol 10:5416–5423PubMed Versteeg R, van der Minne C, Plomp A et al (1990) N-myc expression switched off and class I human leukocyte antigen expression switched on after somatic cell fusion of neuroblastoma cells. Mol Cell Biol 10:5416–5423PubMed
24.
Zurück zum Zitat Cheng NC, Beitsma M, Chan A et al (1996) Lack of class I HLA expression in neuroblastoma is associated with high N-myc expression and hypomethylation due to loss of the MEMO-1 locus. Oncogene 13:1737–1744PubMed Cheng NC, Beitsma M, Chan A et al (1996) Lack of class I HLA expression in neuroblastoma is associated with high N-myc expression and hypomethylation due to loss of the MEMO-1 locus. Oncogene 13:1737–1744PubMed
25.
Zurück zum Zitat Gross N, Beck D, Favre S (1990) In vitro modulation and relationship between N-myc and HLA class I RNA steady-state levels in human neuroblastoma cells. Cancer Res 50:7532–7536PubMed Gross N, Beck D, Favre S (1990) In vitro modulation and relationship between N-myc and HLA class I RNA steady-state levels in human neuroblastoma cells. Cancer Res 50:7532–7536PubMed
26.
Zurück zum Zitat Jass JR, Baker K, Zlobec I et al (2006) Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a ‘fusion’ pathway to colorectal cancer. Histopathology 49:121–131PubMedCrossRef Jass JR, Baker K, Zlobec I et al (2006) Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a ‘fusion’ pathway to colorectal cancer. Histopathology 49:121–131PubMedCrossRef
27.
Zurück zum Zitat Chan TL, Zhao W, Leung SY et al (2003) Cancer Genome Project. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 63:4878–4881PubMed Chan TL, Zhao W, Leung SY et al (2003) Cancer Genome Project. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 63:4878–4881PubMed
28.
Zurück zum Zitat Torlakovic E, Skovlund E, Snover DC et al (2003) Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol 27:65–81PubMedCrossRef Torlakovic E, Skovlund E, Snover DC et al (2003) Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol 27:65–81PubMedCrossRef
29.
Zurück zum Zitat Goldstein NS, Bhanot P, Odish E et al (2003) Hyperplastic-like colon polyps that preceded microsatellite-unstable adenocarcinomas. Am J Clin Pathol 119:778–796PubMedCrossRef Goldstein NS, Bhanot P, Odish E et al (2003) Hyperplastic-like colon polyps that preceded microsatellite-unstable adenocarcinomas. Am J Clin Pathol 119:778–796PubMedCrossRef
Metadaten
Titel
Down-regulation of HLA-A mRNA in peripheral blood mononuclear cell of colorectal cancer
verfasst von
Ming-Chen Zhu
Yi-Jun Xu
Xiong Zou
Feng Yan
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
International Journal of Colorectal Disease / Ausgabe 1/2012
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-011-1315-4

Weitere Artikel der Ausgabe 1/2012

International Journal of Colorectal Disease 1/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.